Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Relmada Therapeutics ( (RLMD) ).
On August 29, 2025, Raj S. Pruthi, MD, Chief Medical Officer-Urology of Relmada Therapeutics, purchased 55,000 shares of the company’s common stock in open market transactions. This purchase may reflect confidence in the company’s future prospects and could impact stakeholder perceptions positively, although the information is not deemed filed for certain regulatory purposes.
The most recent analyst rating on (RLMD) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Relmada Therapeutics stock, see the RLMD Stock Forecast page.
Spark’s Take on RLMD Stock
According to Spark, TipRanks’ AI Analyst, RLMD is a Neutral.
Relmada Therapeutics’ overall score reflects its high-risk, high-reward profile typical of biotechnology firms in developmental stages. The company’s financial performance is weakened by zero revenue and significant cash burn, tempered by strong cash reserves. Strategic pipeline developments and recent acquisitions offer potential upside, but are countered by challenges such as discontinued projects and reliance on external financing. Technical analysis shows short-term momentum, but the overall outlook remains speculative.
To see Spark’s full report on RLMD stock, click here.
More about Relmada Therapeutics
Relmada Therapeutics, Inc. operates in the pharmaceutical industry, focusing on the development of treatments for central nervous system disorders.
Average Trading Volume: 563,909
Technical Sentiment Signal: Sell
Current Market Cap: $37.17M
For detailed information about RLMD stock, go to TipRanks’ Stock Analysis page.